GlassScriptPhysician profile
Zlatan Stepanovic
NPI 1710987003
$9,361.98
in general payments reported to CMS, 2019-2025
47 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $824 · 2021: $1,675 · 2022: $1,391 · 2023: $1,457 · 2024: $1,056 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,051.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,401.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,027.87 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $817.66 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $803.05 | 2019-2025 | Lifevest |
| Pfizer INC. | $548.15 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $500.20 | 2020-2025 | Amvuttra, Onpattro |
| Amgen INC. | $461.56 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $448.59 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $433.39 | 2021-2024 | Verquvo |
| Chiesi USA, INC. | $368.65 | 2019-2025 | Cleviprex, Kengreal |
| Esperion Therapeutics, INC. | $281.23 | 2020-2025 | Nexletol |
| Abiomed | $235.00 | 2024-2025 | Impella |
| Abbott Laboratories | $193.30 | 2020-2025 | Esprit |
| Sanofi-Aventis U.S. LLC | $188.91 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $179.38 | 2019-2024 | Camzyos, Eliquis |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $120.48 | 2021-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $118.44 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $88.67 | 2022-2024 | Uptravi, Opsumit |
| W. L. Gore & Associates, INC. | $82.88 | 2022-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Boston Scientific Corporation | $82.61 | 2025 | Watchman Flx |
| Medtronic Vascular, INC. | $81.50 | 2019-2020 | |
| Itamar Medical INC | $73.57 | 2023-2024 | Watchpatone |
| Amarin Pharma, INC. | $71.13 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $68.36 | 2021-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $63.29 | 2019 | |
| Lundbeck LLC | $60.93 | 2019-2020 | |
| Edwards Lifesciences Corporation | $48.09 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $45.75 | 2024 | |
| Inari Medical, INC. | $44.74 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kowa Pharmaceuticals America, INC. | $41.46 | 2019-2023 | Livalo |
| Gilead Sciences, INC. | $40.10 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $34.52 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $31.83 | 2019-2021 | |
| Cardiovascular Systems INC. | $29.45 | 2019-2020 | |
| Bridgebio Pharma, INC. | $25.58 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $24.13 | 2025 | Assure Wcd |
| Vifor Pharma, INC. | $23.68 | 2021 | |
| Allergan, INC. | $23.31 | 2019 | |
| Impulse Dynamics (USA) INC. | $20.83 | 2022 | |
| Heartflow, INC. | $19.00 | 2024 | |
| Akcea Therapeutics, INC. | $18.95 | 2020 | |
| Cordis US Corp. | $18.33 | 2025 | Mynx Control Venous |
| Angiodynamics, INC. | $18.18 | 2021 | |
| Glaxosmithkline, LLC. | $15.36 | 2025 | Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $14.48 | 2024 | Arcalyst |
| Hikma Pharmaceuticals USA | $12.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zlatan Stepanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.